Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Lung
Erschienen in:

06.11.2019 | PULMONARY HYPERTENSION

Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway

verfasst von: Aravind A. Menon, Sandeep Sahay, Lewis E. Braverman, Harrison W. Farber

Erschienen in: Lung | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Epoprostenol, a synthetic prostaglandin I2 (PGI2) analog, has been the mainstay of treatment for severe pulmonary arterial hypertension (PAH) for the last two decades. Treprostinil, another synthetic prostaglandin analog, and selexipag, an oral selective Inositol Phosphate (IP) prostacyclin receptor agonist, have also been approved for treatment of PAH. Prostacyclin and its analogs cause a variety of side effects in patients with PAH; however, thyroid dysfunction is rarely reported.

Methods

After treating an index case of thyroid dysfunction occurring after initiation of epoprostenol, we reviewed our databases of PAH patients treated with epoprostenol, treprostinil or selexipag to identify the occurrence of this association.

Results

We identified six cases of thyroid dysfunction in our cohort: five after initiation of an intravenous prostacyclin (epoprostenol) and one after initiation of an oral prostacyclin receptor agonist (selexipag). Four of the patients presented with hyperthyroidism and two with a large autoimmune goiter. Graves’ disease was seen in three patients, Hashimoto’s disease in two patients and thyrotoxicosis in one patient.

Conclusion

Therapy with medications targeting the prostacyclin pathway is a potential risk factor for the development of symptomatic thyroid disease.
Literatur
1.
Galiè N, Humbert M, Vachiery JL et al (2016) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1):67–119PubMed
2.
Badesch DB, Raskob GE, Elliott CG et al (2010) Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 137(2):376–387PubMed
3.
Curnock AL, Dweik RD, Higgins BH, Saadi HF, Arroliga AC (1999) High prevalence of hypothyroidism in patients with primary pulmonary hypertension. Am J Med Sci 318(5):289–292PubMed
4.
Arroliga AC, Dweik RA, Rafanan AL (2000) Primary pulmonary hypertension and thyroid disease. Chest 118(4):1224–1225PubMed
5.
Kashyap AS, Kashyap S (2001) Thyroid disease and primary pulmonary hypertension. JAMA 285(22):2853–2854PubMed
6.
Marvisi M, Brianti M, Marani G, Del Borello P, Bortesi ML, Guariglia A (2002) Hyperthyroidism and pulmonary hypertension. Respir Med 96(4):215–220PubMed
7.
Chu JW, Kao PN, Faul JL, Doyle RL (2002) High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 122(5):1668–1673PubMed
8.
Iervasi G, Molinaro S, Landi P et al (2007) Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 167(14):1526–1532PubMed
9.
Iervasi G, Pingitore A, Landi P et al (2003) Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 107(5):708–713PubMed
10.
Miura Y, Fukumoto Y, Sugimura K et al (2010) Identification of new prognostic factors of pulmonary hypertension. Circ J 74(9):1965–1971PubMed
11.
Vallabhajosula S, Radhi S, Alalawi R, Raj R, Nugent K, Cevik C (2011) Hyperthyroidism and pulmonary hypertension: an important association. Am J Med Sci 342(6):507–512PubMed
12.
Macchia A, Marchioli R, Tognoni G, Scarano M, Marfisi R, Tavazzi L, Rich S (2010) Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J 159(2):245–257PubMed
13.
Humbert M, Ghofrani HA (2016) The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax 71(1):73–83PubMed
14.
Rubin LJ, Mendoza J, Hood M et al (1990) Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 112(7):485–491PubMed
15.
Coeytaux RR, Schmit KM, Kraft BD et al (2014) Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Chest 145(5):1055–1063PubMed
16.
Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS (1994) Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121(6):409–415PubMed
17.
McLaughlin VV, Shillington A, Rich S (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106(12):1477–1482PubMed
18.
Barst RJ, Rubin LJ, Long WA et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334(5):296–301PubMed
19.
Badesch DB, Tapson VF, McGoon MD et al (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 132(6):425–434PubMed
20.
Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM (2003) Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 167(4):580–586PubMed
21.
Sitbon O, Channick R, Chin KM et al (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373(26):2522–2533PubMed
22.
Ferris A, Jacobs T, Widlitz AB, Robyn J, Morse JH (2001) Pulmonary arterial hypertension and thyroid disease. Chest 119(6):1980PubMed
23.
Davies A, Frost A (1997) Epoprostenol-associated thyropathy in PPH patients [abstract]. Am J Respir Crit Care Med 155(suppl):A630
24.
Gu Y, Schwarcz MD, Weiss IA (2016) Pulmonary hypertension aggravated by hyperthyroidism: a case report [abstract]. Endocr Rev 37(2):Supplement 1
25.
Nakchbandi IA, Wirth JA, Inzucchi SE (1999) Pulmonary hypertension caused by Graves’ thyrotoxicosis: normal pulmonary hemodynamics restored by 131I treatment. Chest 116(5):1483–1485PubMed
26.
Marvisi M, Balzarini L, Mancini C, Mouzakiti P (2013) Thyroid gland and pulmonary hypertension. What’s the link? Panminerva Med 55(1):93–97PubMed
27.
Castillo MP, García FH, Montero PB, González RL, Ocaña CM, Sánchez JR (2009) Thyroid dysfunction in patients with pulmonary arterial hypertension. A cohort study of 58 patients. Med Clin (Barc) 132(18):695–700
28.
Srimatkandada P, Farber HW, Coviello AD (2014) Rapid development of compressive goiter and severe hyperthyroidism in a patient with pulmonary arterial hypertension after treatment with epoprostenol [abstract]. Endocr Rev 35(3)
29.
Srimatkandada P, Coviello AD (2015) Severe autoimmune hyperthyroidism in two patients with pulmonary arterial hypertension after treatment with epoprostenol. J Thyroid Disord Ther. 4(176):2
30.
Funasako M, Miyaji K, Sakuma M, Takagi Y, Kyotani S, Nakanishi N (2010) Long-term epoprostenol infusion therapy could induce hyperthyroidism in patients with idiopathic and hereditary pulmonary arterial hypertension [abstract]. Circulation 122(21_MeetingAbstracts):Supplement 1
31.
Galie N, Rubin LJ, Hoeper MM et al (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630):2093–2100PubMed
32.
Galiè N, Olschewski H, Oudiz RJ et al (2008) Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117(23):3010–3019PubMed
33.
Rubin LJ, Badesch DB, Fleming TR et al (2011) Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 140(5):1274–1283PubMed
34.
Zor U, Kaneko T, Lowe IP, Bloom G, Field JB (1969) Effect of thyroid-stimulating hormone and prostaglandins on thyroid adenyl cyclase activation and cyclic adenosine 3′, 5′-monophosphate. J Biol Chem 244(19):5189–5195PubMed
35.
Virgolini I, Steurer G, Keminger K, Sinzinger H, Kraupp O (1987) Evaluation of prostaglandin receptors in the human thyroid gland. Prog Clin Biol Res 242:35–42PubMed
36.
Kasai K, Hiraiwa M, Suzuki Y et al (1986) Prostacyclin stimulation of adenylate cyclase activity in human thyroid membranes. Horm Metab Res 18(09):625–629PubMed
37.
Chadha C, Pritzker M, Mariash C (2009) Effect of epoprostenol on the thyroid gland: enlargement and secretion of thyroid hormone. Endocr Pract 15(2):116–121PubMed
38.
Satoh M, Aso K, Nakayama T, Saji T (2017) Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension. Endocr J 64(12):1173–1180PubMed
39.
Virgolini I, Hermann M, Sinzinger H (1989) Decrease of the prostaglandin I2 binding capacity in thyroids from patients with Graves’ disease. Prostaglandins Leukot Essent Fatty Acids 37(2):121–128PubMed
40.
Yoh-ichiro K, Kanemaru Y, Noguchi T, Onaya T (1987) Circulating prostacyclin and thromboxane in patients with Graves’ disease. Prostaglandins Leukot Essent Fatty Acids 26(1):75–84
41.
Brix TH, Hegedüs L (2011) The complexity of the etiology of autoimmune thyroid disease is gravely underestimated. Thyroid 21(12):1289–1292PubMed
42.
Frey A, Kroiss M, Berliner D et al (2013) Prognostic impact of subclinical thyroid dysfunction in heart failure. Int J Cardiol 168:300–305PubMed
Metadaten
Titel
Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway
verfasst von
Aravind A. Menon
Sandeep Sahay
Lewis E. Braverman
Harrison W. Farber
Publikationsdatum
06.11.2019
Verlag
Springer US
Erschienen in
Lung / Ausgabe 6/2019
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-019-00283-8

Weitere Artikel der Ausgabe 6/2019

A Cast of the Left Bronchial Tree

  • LUNG IMAGES

Evaluation of Renin and Soluble (Pro)renin Receptor in Patients with IPF. A Comparison with Hypersensitivity Pneumonitis

  • Interstitial Lung Disease

Weight Status and Respiratory Health in Asthmatic Children

  • ASTHMA

In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis: A US Cohort Study

  • Open Access
  • INTERSTITIAL LUNG DISEASE

Development of Chronic Pseudomonas aeruginosa-Positive Respiratory Cultures in Children with Tracheostomy

  • RESPIRATORY INFECTIONS

The Effects of Health Disparities on Perceptions About Lung Cancer Screening (LCS): Survey Results of a Patient Sample

  • LUNG CANCER

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mit Lidocain kommt der Darm nicht schneller in Schwung

Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.

Koronare Herzkrankheit: Das waren die Top-Studien in 2024

Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Inhalative Steroide bei COPD nicht kardioprotektiv

  • 10.01.2025
  • COPD
  • Nachrichten

Ob inhalative Kortikosteroide (ICS) COPD-Kranke außer vor akuten Exazerbationen auch vor kardiovaskulären Komplikationen schützen können, ist unklar. Eine bevölkerungsbasierte Studie aus England spricht nicht dafür.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise